MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

Phase 1
Completed
Conditions
Psychotic-like Symptoms
Ketamine-Induced Brain Activity Changes
Interventions
Drug: Ketamine
Drug: TAK-063
Drug: TAK-063 Placebo
First Posted Date
2013-07-04
Last Posted Date
2017-01-12
Lead Sponsor
Takeda
Target Recruit Count
27
Registration Number
NCT01892189
Locations
🇺🇸

The Brain Institute, University of Utah, Salt Lake City, Utah, United States

Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes

First Posted Date
2013-07-01
Last Posted Date
2016-11-28
Lead Sponsor
Takeda
Target Recruit Count
647
Registration Number
NCT01890122

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: TAK-063
Drug: TAK-063 Placebo
First Posted Date
2013-06-18
Last Posted Date
2016-10-28
Lead Sponsor
Takeda
Target Recruit Count
77
Registration Number
NCT01879722

Observational Study in Preterm Neonates Who Are Sufficiently Stable on Non-Invasive Ventilatory Support

Completed
Conditions
Infant Respiratory Distress Syndrome
Non-invasive Ventilatory Support
Interventions
Other: Preterm Neonates
First Posted Date
2013-05-24
Last Posted Date
2014-08-22
Lead Sponsor
Takeda
Target Recruit Count
40
Registration Number
NCT01861795

Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency

Phase 4
Completed
Conditions
Chronic Venous Insufficiency
Interventions
Drug: Coumarin/troxerutin
Drug: Placebo
First Posted Date
2013-05-07
Last Posted Date
2016-11-11
Lead Sponsor
Takeda
Target Recruit Count
829
Registration Number
NCT01848210

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

First Posted Date
2013-04-17
Last Posted Date
2015-09-28
Lead Sponsor
Takeda
Target Recruit Count
96
Registration Number
NCT01834274

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Phase 3
Terminated
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: TAK-875 Placebo
Drug: TAK-875
Drug: Glimepiride
First Posted Date
2013-04-11
Last Posted Date
2016-06-01
Lead Sponsor
Takeda
Target Recruit Count
33
Registration Number
NCT01829477

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Phase 3
Terminated
Conditions
Diabetes
Interventions
Drug: TAK-875
Drug: Placebo
First Posted Date
2013-04-11
Last Posted Date
2016-06-01
Lead Sponsor
Takeda
Target Recruit Count
90
Registration Number
NCT01829464
Locations
🇺🇸

Apex Medical Research, MI, Inc, Chicago, Illinois, United States

Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Biological: TDV
Drug: Placebo
First Posted Date
2013-01-10
Last Posted Date
2019-07-18
Lead Sponsor
Takeda
Target Recruit Count
67
Registration Number
NCT01765426
Locations
🇺🇸

University of Texas Medical Branch, Galveston, Texas, United States

🇺🇸

Group Health Research Institute, Seattle, Washington, United States

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Febuxostat
Drug: Febuxostat placebo
First Posted Date
2013-01-09
Last Posted Date
2016-04-13
Lead Sponsor
Takeda
Target Recruit Count
30
Registration Number
NCT01763996
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy